SMMTbenzinga

JMP Securities Initiates Coverage On Summit Therapeutics with Market Outperform Rating, Announces Price Target of $32

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on November 4, 2024 by benzinga

    JMP Securities Initiates Coverage On Summit Therapeutics with Market Outperform Rating, Announces Price Target of $32 | SMMT Stock News | Candlesense